| Autor: |
Stebler-Fontaine, Laura, Rossel, Anne, Marti, Christophec, Righini, Marc Philip, Robert-Ebadi, Helia |
| Jazyk: |
francouzština |
| Rok vydání: |
2019 |
| Předmět: |
|
| Zdroj: |
Revue médicale suisse, Vol. 15, No 674 (2019) pp. 2232-2235 |
| ISSN: |
1660-9379 |
| Popis: |
The use of direct oral anticoagulants (DOACs) has been largely -implemented in the management of venous thromboembolic disease in non-cancer patients. In cancer-associated thrombosis, low molecular weight heparins (LMWHs) and especially dalteparin have long been the reference standard therapy. Following the publication of two randomised trials comparing edoxaban and rivaroxaban to -dalteparin, DOACs now represent an alternative with an interesting efficacy and safety profile. Moreover, they offer the comfort of an oral administration and a lower cost. In patients with gastrointestinal or genitourinary cancers however, a higher bleeding risk has been shown with DOACs. LMWHs thus remain the treatment of choice in this group of patients. |
| Databáze: |
OpenAIRE |
| Externí odkaz: |
|
